ArticleAnimal models and experimental medicine2026
Expanded characterization of the valproic acid zebrafish larval model of autism spectrum disorder: Insights into dysregulation in the gut.
Article in Animal models and experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Expanded characterization of the valproic acid zebrafish larval model of autism spectrum disorder: Insights into dysregulation in the gut.Animal models and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundRelative lack of data on mechanisms underpinning poor gastrointestinal (GI) health in autism spectrum disorder (ASD) limits patient management strategies. Although the valproic acid (VPA) model of ASD is widely used, a comprehensive profile of the model in zebrafish is still lacking, and almost no data are available on ASD-like GI symptomology or underlying mechanisms.
methodsASD-like craniofacial morphology, anxiety-like behavior, GI anatomical and functional dysregulation, and dysregulation of the monoaminergic system in both the brain and the gut were simultaneously assessed in zebrafish larvae at 7 days postfertilization.
resultsVPA exposure was associated with increased intraocular distance, neuroligin 3 (NLGN3) dysregulation, decreased muscle tone, and an anxious phenotype (increased thigmotaxis and dark zone preference [light-dark preference test]). In the brain, protein expression levels of tryptophan hydroxylase 2 (TPH2) and serotonin (5-HT), but not serotonin transporter (SERT), were downregulated, as well as tyrosine hydroxylase (TH) and dopamine transporter (DAT), whereas dopamine (DA) was upregulated. In the gut, upregulated serotonergic (increased TPH1 and 5-HT) and downregulated dopaminergic (decreased TH, increased DAT) protein expression was linked to thinner-walled, longer intestinal tracts, and decreased spontaneous peristaltic activity.
conclusionsDopaminergic dysregulation aligns with the ASD literature. Novel findings include an association of hyposerotonergic tone with anxiety-like outcomes as core symptomology in ASD. Furthermore, we demonstrate compartment-specific dopaminergic and serotonergic dysregulation in the gut, which provides support for relatively decreased gut motility in ASD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.